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ABSTRACT 
 
Cryptogenic organizing pneumonia (COP) is a 
distinct histopathologic entity characterized by 
Masson bodies which are intraalveolar buds of 
granulation tissue; consisting of connective 
tissue and myofibroblasts. This pathologic pat-
tern when present with the characteristic imag-
ing and clinical features of COP defines the 
diagnosis of the disease. A specific etiology is 
not found. Treatment with corticosteroids re-
sults in a rapid clinical and imaging improve-
ment but unfortunately relapses are common 
upon decreasing the dose or stopping the treat-
ment. This case report describes a typical case 
of COP with the characteristic improvement 
with corticosteroid therapy and relapse upon 
treatment taper 
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CASE REPORT 
 
A 52-year-old otherwise healthy woman is ad-
mitted to our hospital due to dry cough, dyspnea 
on moderate exertion, fever (not quantified) and 
night sweats for one month and a pulmonary 
right basal consolidation. Prior to admission the 
patient received treatment with Levofloxacin 
750 mg per day for seven days without im-
provement. 
 
On physical exam upon admission she was 
afebrile, tachycardic (heart rate 114 bpm), blood 
pressure was 130/70 mmHg and not hypoxemic. 
She was alert and oriented; pulmonary ausculta-
tion revealed crackles with diminished breath 
sounds over the right lower hemi thorax. The 
rest of the physical exam was unremarkable. 
 
The erythrocyte sedimentation rate (ESR) was 
65 mm. h-1, C reactive protein (CRP) was 16.8 
mg/dl, white blood cell (WBC) count was in-
creased at 152.000 with a left shift. The rest of 
routine laboratory tests including electrolytes, 
renal and liver function were normal. Tests for 
collagen vascular disease including RF and 
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ANA were negative. Brain natriuretic peptide 
(BNP) and procalcitonin were within normal 
limits. Cultures of bronchial aspirate for myco-
bacteria and serology of respiratory viruses was 
negative, immunoglobulin levels were normal.  
 
 
 
 
 
 
Figure 1. CT of the lung showed a right posterior 
segmentary consolidation. 
 
You can find a full video of this CT scan in: 
 
https://www.youtube.com/channel/UCgRZTxrN
cN6zMkw0ih9Rkaw  
 
Computed tomography (CT) of the lung showed 
a right basal posterior segmentary consolidation, 
a pulmonary embolism was ruled out with an 
angio-CT (figure 1). Bronchial lavage (BAL) 
differential cell count revealed lymphocytosis 
and an increase in polymorphonuclear cells (cell 
count: 18.3% macrophages, 61.8% lymphocytes, 
18.2% polymorphonuclear and 1.8% bronchial 
cells).  
The diagnostic impression was an organized 
pneumonia due to the nonspecific inflammatory 
lymphoplasmocytic cellularity. Specimens were 
smear and culture negative. Cytologic analysis 
was normal. Pulmonary function tests showed a 
forced vital capacity (FVC) 64% of predicted 
value, forced expiratory volume in 1 sec. 
(VEF1) 63% pred. and FEF 25-75% 52% pred. 
 
The pathologic review of the lung specimen had 
revealed Masson bodies; polypoid structures 
consisting of fibroblasts within the alveolar 
ducts and bronchioles. A chronic interstitial 
inflammatory infiltrate was present with promi-
nent hyperplasia of type II pneumocytes and 
intraalveolar macrophages (figure 2). The latter 
observations were consistent with the diagnosis 
of cryptogenic organizing pneumonia. 
 
 
 
 
Figure 2. Chronic interstitial inflammatory infil-
trate was present with prominent hyperplasia of 
type II pneumocytes and intraalveolar macro-
phages. 
 
 
During the hospital stay the patient did not re-
ceive antibiotics. The diagnosis of cryptogenic 
organizing pneumonia was made but steroid 
treatment was not started pending the tuberculin 
test result (which was negative). She was dis-
charged with ongoing pulmonary clinical symp-
toms. 
 
The patient was seen in the outpatient clinic two 
weeks after discharge and treatment with 50 mg 
of prednisone daily was started. She underwent 
the six-minute walk test (6MWT) and reached 
420 mts. presenting desaturation with a  pO2 62 
mmHg. The DLco was 75% pred. The plethis-
mography showed a VC of 73% pred. with 
normal TLC and RV values. Pulmonary func-
tion tests had a FVC 73% pred. and normal 
VEF1 and FEF25-75% values.  The ESR was 21 
mm. h-1 and CRP 0.33 mg/dl. 
 
Two months after discharge the patient was seen 
in the outpatient clinic. On physical exam, pul-
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monary auscultation was normal. The chest x-
ray showed a significant improvement with 
radiopaque lines probably due to interstitial 
fibrosis. CRP was 0.36 mg/dl. Pulmonary func-
tion tests were normal and on 6MWT she 
walked 70 m further without desaturation. 
 
Three months after discharge the patient contin-
ued asymptomatic and the dose of prednisone 
was reduced to 25 mg daily. Five months later 
she presented with a normal pulmonary exam as 
well as normal chest x-ray and pulmonary func-
tion tests. ESR was 65 mm. h-1, the dose of 
prednisone was decreased at a rate of 5 mg per 
week until reaching 10 mg daily. 
 
In the following year after discharge, the patient 
continued asymptomatic and with normal pul-
monary function tests. During this period of 
time the dose of prednisone was reduced to 5 
mg daily and eventually to 5 mg every 48 hours. 
 
One week after the decrease in dose of predni-
sone to 5 mg every 48 hours, the patient pre-
sents with dyspnea, cough and thoracic pain. On 
physical exam crackles are present on ausculta-
tion of the right upper hemi thorax. Chest x-ray 
shows an alveolar infiltrate in the right upper 
lobe (figure 3). The dose of prednisone is in-
creased to 25 mg daily. One week later the pa-
tient is found to be asymptomatic and pulmo-
nary auscultation is normal; ESR is 5 mm. h-1. 
 
 
 
 
Figure 3. Chest x-ray: alveolar infiltrate in the right 
upper lobe. 
 
 
In the following four months the patients con-
tinues asymptomatic. Pulmonary exam, chest x-
ray and pulmonary function tests are normal; 
prednisone treatment is decreased to a dose of 5 
mg per day. Prophylaxis for Pneumocystis jiro-
veci is started with Trimethoprim- sulfamethox-
azole (160 mg/800 mg) three times per week. 
Pulmonary CT shows diffuse laminar atelectasis 
prominent in the right upper lobe. Currently the 
patient has been asymptomatic for the last five 
months on prednisone 5 mg daily and continues 
follow up in the outpatient clinic. 
 
 
DISCUSSION 
 
Cryptogenic organizing pneumonia (COP) is the 
idiopathic form of organizing pneumonia con-
sisting of a diffuse interstitial lung disease af-
fecting the alveolar walls as the most important 
area of injury, alveolar ducts, respiratory bron-
chioles and distal bronchioles.(1-3) It is only 
considered to be cryptogenic when there is not a 
definite etiology of organizing pneumonia.(4) 
 
An incidence of 6 to 7 cases per 100.000 hospi-
tal inpatients was found in one study,(5) the 
annual incidence in other studies has been 1.1 
per 100.000.(6) 
 
Pathogenesis 
 
The most interesting characteristic of COP is 
that it is not associated with progressive irre-
versible fibrosis; the fibrosis seen in COP usual-
ly has a marked reversibility with corticoster-
oids differentiating COP from usual interstitial 
pneumonia (UIP). 
 
The first stage in the process of organization of 
the fibrosis seen in COP consists of the for-
mation of fibrinoid inflammatory cell clusters, 
which consist of inflammatory cells including 
polymorphonuclears, lymphocytes, mast cells 
and plasma cells with bands of fibrin.(7) 
 
The formation of fibroinflammatory buds (Mas-
son bodies) is characteristic of the second stage; 
inflammatory cells are less numerous and fibrin 
is fragmented. The presence of mitotic figures is 
proof of the migration and proliferation of fi-
broblasts from the interstitium to the basal lami-
nae and their colonization of fibrin remnants. A 
reepithelialisation of the basal laminae takes 
place because of the proliferation of alveolar 
cells; this reepithelialisation is vital for the 
preservation of the integrity of the structure of 
the alveolar unit.(8) 
 
The final stage of the process of organization is 
characterized by mature fibrotic buds with al-
most no inflammatory cells and the fibrin in the 
alveolar lumen has disappeared; layers of con-
nective tissue alternate with concentric rings of 
fibroblasts.(9) 
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The intra-alveolar buds in COP are character-
ized by prominent capillarisation.(10) Intraalveo-
lar buds express basic fibroblast growth factor 
and vascular endothelial growth factor.(11) These 
growth factors mediate angiogenesis and are 
important for the reversal of buds seen in COP 
with treatment. 
 
Clinical Features 
 
The mean age of onset of COP is 50-60 years; 
males and females are affected equally. Clinical 
manifestations include progressive mild dysp-
nea, cough, fever, malaise, anorexia and weight 
loss. Uncommon manifestations include hemop-
tysis, night sweats, mild arthralgia and chest 
pain.(12,13) Diagnosis is many times delayed 
because of the nonspecific manifestations. On 
physical exam the pulmonary exam may present 
focal sparse crackles or may be normal. 
 
Imaging 
 
COP has three patterns of presentation on imag-
ing studies; solitary opacity (focal COP), multi-
ple alveolar opacities (typical COP) and infiltra-
tive opacities (infiltrative COP). CT images are 
characteristic and yield the correct diagnosis in 
approximately 80% of cases.(14) 
 
The most frequent imaging seen in COP con-
sists of multiple alveolar opacities, which are 
mostly peripheral, bilateral and migratory. Their 
size varies between a complete lobe and a few 
centimeters; air bronchogram may be present. 
When patients with COP present with the typi-
cal imaging characteristics of the disease on CT 
scan or HRCT scan the differential diagnosis 
narrows down to include bronchioalveolar lung 
carcinoma, idiopathic chronic eosinophilic 
pneumonias and low-grade lymphoma.(15) 
 
Patients presenting with infiltrative or focal 
COP on imaging are usually diagnosed through 
histopathology since these patterns are not char-
acteristic of the disease. 
 
Lung Function Tests 
 
On spirometry patients with COP frequently 
have a moderate to mild restrictive ventilatory 
defect. Obstructive abnormalities are not char-
acteristic of the disease, although they may be 
seen in patients with underlying chronic ob-
structive pulmonary disease or smoking. The 
reduction of pulmonary restriction is propor-
tional to the reduction of the transfer factor of 
the lung for carbon monoxide. Hypoxemia both 
with mild exertion and at rest are usually 
mild.(16,17) 
Bronchioalveolar lavage (BAL) is indicated in 
all cases where COP is being considered as a 
differential diagnosis. BAL may evidence neo-
plastic pathologies (bronchioalveolar carcinoma 
or lymphoma) as well as active infections. Pa-
tients with COP characteristically present a 
BAL with a mixed pattern differential cell 
count; consisting of an increased percentage of 
lymphocytes (20-40%), neutrophils (approxi-
mately 10%) and eosinophils (approximately 
5%); the percentage of eosinophils is character-
istically lower than that of lymphocytes. The 
CD4/ CD8 ratio is usually low.(18,19) 
 
Blood tests may present a mild leukocytosis 
with a mild increase in neutrophils. Eosinophilia 
is not present. Erythrocyte sedimentation rate 
and C- reactive protein are characteristically 
elevated.(20) 
 
Diagnosis of COP 
 
The diagnosis of COP requires the histopatho-
logic diagnosis of organizing pneumonia and 
the exclusion of any specific cause. Histopatho-
logically the typical features of organizing 
pneumonia are buds of granulation tissue (Mas-
son bodies) consisting of myofibroblasts- fibro-
blasts embedded in connective tissue. These 
buds may extend through the interalveolar pores 
presenting a “butterfly pattern”.(21,22)  
 
Foamy alveolar macrophages are present as well 
as mild interstitial inflammation. Special stains 
to exclude infection are usually the norm in 
patients being studied for possible COP. It is 
imperative to have enough amount of lung tis-
sue to be able to perform a meticulous histo-
pathologic study; because of this, video assisted 
thoracoscopy is usually performed in these 
patients to obtain lung tissue of sufficient size. 
However in some cases, such as the one pre-
sented here, the finding of intra alveolar buds is 
seen on transbronchial biopsy specimens.(23) 
 
Organizing pneumonia within  
a specific content 
 
Organizing pneumonia can be present as a pul-
monary manifestation in patients with connec-
tive tissue disorders (dermatomyositis-
polymiositis, systemic lupus erythematosus, 
rheumatoid arthritis, CREST, scleroderma and 
Sjogren syndrome). It may also present with 
malignancies, hematological diseases and in-
flammatory bowel disease. These disorders 
must be considered and ruled out as appropriate 
when making the diagnosis of COP. That said, 
patients with COP have been reported to have 
articular pain without an underlying disorder.(13) 
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Treatment of COP 
 
Treatment decisions in COP are usually based 
on practice guidelines since treatment of COP 
has not been studied in randomized clinical 
trials.(24) Initiation as well as choice of first line 
therapy is usually based on pulmonary function 
on presentation, the severity of clinical symp-
toms and the extent and severity of disease on 
imaging studies as well as the progression of the 
disease.(25) 
 
Patients with COP who have mild symptoms as 
well as mild abnormalities on pulmonary func-
tion tests are usually monitored every 2-3 month 
intervals without treatment.(26) 
 
For symptomatic patients with moderate to 
severe respiratory impairment glucocorticoid 
treatment is recommended; the equivalent of 1 
mg/kg per day (maximum 100 mg daily) is 
given as a single dose in the morning. Predni-
sone is the drug of choice and the initial dose is 
given for up to eight weeks, if the patient shows 
improvement the dose is tapered to 0.5 
mg/kg/day for the next six weeks and then 
gradually tapered to nothing as long as the pa-
tient is stable.(26) After the cessation of treatment 
with prednisone the patient should be followed 
for the next twelve months and the chest radio-
graph is repeated every three months during this 
period of time.(27) 
 
Patients with impending respiratory failure or 
rapidly progressive COP are treated with high 
dose intravenous glucocorticoid therapy 
(methylprednisolone 1.000 mg intravenously for 
five days) as the treatment of choice.(28,29) 
 
Addition of a second immunosuppressant agent 
is used when patients fail to respond to initial 
glucocorticoid therapy, have frequent recurrenc-
es (more than three) or those who have a fulmi-
nant presentation; azathioprine or cyclophos-
phamide are the medications of choice in these 
particular COP cases.(30-32) Patients who are 
going to receive azathioprine should undergo 
analysis of the enzyme thiopurine methyltrans-
ferase gene since a deficiency of this enzyme 
predicts those individuals with a higher risk of 
severe toxic events from this medication.(33) 
 
Treatment with glucocorticoids results in clini-
cal improvement and normalization of chest 
imaging in a short period of time (days to 
weeks) in the majority of patients. Oral gluco-
corticoid therapy is tapered over 6 to 18 months. 
Relapses are seen frequently upon reducing the 
dose of treatment such as the relapse in the case 
presented here; this causes prolongation of 
treatment.(25)  
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